Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: paul heath who wrote (13168)	8/12/1998 7:28:00 PM
From: VLAD	Respond to of 23519

Alibra is Vivus' next generation ED product. It will have but one dose level and works better than MUSE.

To: paul heath who wrote (13168)	8/12/1998 7:34:00 PM
From: DaiS	Respond to of 23519

Paul, Alibra is a new version of muse that contains the drug prazosin, an alpha blocker, as well as alprostadil the drug currently in muse. Experiments carried out by Vivus and others suggest that Alibra has a higher success rate than muse. Vivus should be marketing alibra by 2000 if all goes well with the trials, maybe earlier. We learnt yesterday that Vivus plan to market only a single strength alibra which should eliminate the problem you mentioned in an earlier post, that of men being unsuccesful on the lower muse doses. DaiS